Congress considers biosimilars
23 March 2009
Eileen McDermott, New York
The US House of Representatives is considering a bill that would establish a framework for allowing generic biologics to enter the US market
The Pathway for Biosimilars Act was re-introduced this congressional session by US representatives Anna Eshoo, a Democrat from California, Jay Inslee, a Democrat from Washington and Joe Barton, a Republican from Texas.
Generic biologics, or biosimilars, are products that attempt to replicate biologics – medicines which involve living organisms – and are similar, but not identical to, the innovator drug. Like their pharmaceutical counterparts, they are offered at discounted...
Only subscribers have complete access to Managing IP Magazine,
log in or
subscribe now.
Alternatively take a
free trial, giving you 48-hour access to Managing IP Magazine (some articles and surveys may be excluded).
Subscribe Now
This article is available to subscribers. Please click subscribe to read the rest of the article.
Subscribe
Take a free trial
Please take a free 48-hour trial to gain limited access. Some articles and surveys may be excluded.
Take a free trial